The 5-HT6 Receptor Antagonist SB-271046 Reverses Scopolamine-Disrupted Consolidation of a Passive Avoidance Task and Ameliorates Spatial Task Deficits in Aged Rats
Open Access
- 22 October 2003
- journal article
- research article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 29 (1) , 93-100
- https://doi.org/10.1038/sj.npp.1300332
Abstract
The highly potent and selective 5-HT6 receptor antagonist SB-271046 [5-chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide] has previously been demonstrated to improve retention significantly in a spatial water maze paradigm in adult rats. However, SB-271046 did not have any effect on task acquisition. As these apparently contradictory findings may be reconciled by a prime influence of SB-271046 on memory consolidation, the ability of this compound to reverse the discrete temporal action of a cholinergic antagonist in the 6-h period following passive avoidance training was investigated. SB-271046, given orally, by gavage, 30 min prior to training Wistar rats in a step-through, light–dark passive avoidance task, was found to reverse significantly the amnesia produced by administering scopolamine (0.8 mg/kg, intraperitoneal) in the 6-h post-training period. The effect was dose-dependent over a range of 3–20 mg/kg. Further, we investigated the cognition-enhancing effects of chronic SB-271046 administration (10 or 20 mg/kg/day; 40 days) on the acquisition and consolidation of a water maze spatial learning task in a population of 20-month-old Wistar rats with age-related learning deficits. Drug treatment progressively and significantly decreased platform swim angle and escape latencies over the five sequential trials on four consecutive daily sessions compared to vehicle-treated controls. SB-271046 also improved task recall as measured by significant increases in the searching of the target quadrant on post-training days 1 and 3, when the animals would have been substantially drug-free. This significant improvement of task recall suggests SB-271046, in addition to inducing symptomatic cognition-enhancing actions, also attenuates age-related decline in neural function.Keywords
This publication has 32 references indexed in Scilit:
- In vivo effects of the 5‐HT6 antagonist SB‐271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5‐HT, glutamate and aspartateBritish Journal of Pharmacology, 2000
- 5-HT system and cognitionNeuroscience & Biobehavioral Reviews, 1999
- 5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): A Potent, Selective, and Orally Bioavailable 5-HT6 Receptor AntagonistJournal of Medicinal Chemistry, 1999
- Effects of age on water escape behavior and on repeated acquisition in ratsBehavioral and Neural Biology, 1993
- A Novel Rat Serotonin (5-HT6) Receptor: Molecular Cloning, Localization and Stimulation of cAMP AccumulationBiochemical and Biophysical Research Communications, 1993
- Cholinergic and dopaminergic agents which inhibit a passive avoidance response attenuate the paradigm-specific increases in NCAM sialylation stateJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1993
- Spatial learning deficits in old rats: A model for memory decline in the agedNeurobiology of Aging, 1988
- Alzheimer's Disease: A Disorder of Cortical Cholinergic InnervationScience, 1983
- The Cholinergic Hypothesis of Geriatric Memory DysfunctionScience, 1982
- Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal ForebrainScience, 1982